[c-myc and c-Ha-ras proto-oncogenes in cervical cancer: prognostic value].
The biological behaviour of invasive carcinoma of the uterine cervix is not always predictable. It is therefore important to establish new biological markers which could be useful in determining a more reliable prognosis. We have analyzed the c-Ha-ras and c-myc proto-oncogenes in a large series (154 cases) of cervical cancers at various clinical stages. Alterations of c-Ha-ras (deletion, mutation) and c-myc (amplification) were frequently observed in cervical cancers and were shown to be associated with tumor progression. Furthermore, c-myc overexpression, when detected in early cervical cancers, provides a means of identifying patients at high risk of early recurrence.
Laboratoire de pharmacologie clinique et moléculaire, Institut Gustave-Roussy, Villejuif, France.
G
G
Riou
Z M
ZM
Sheng
D
D
Zhou
A
A
Lusinchi
V
V
Le Doussal
M
M
Barrois
D014408:Biomarkers, Tumor / Q000235:genetics; D002872:Chromosome Deletion; D005260:Female; D005784:Gene Amplification / Q000235:genetics; D011905:Genes, ras; D006801:Humans; D009154:Mutation; D009857:Oncogenes; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology
D014408:Biomarkers, Tumor
Les proto-oncogènes c-myc et c-Ha-ras dans les cancers du col de l'utérus: intérêt pronostique.